Interferon for melanoma.
Richtig
Erika
E
Langmann
Gerald
G
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015353:Eye Enucleation; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality; D009362:Neoplasm Metastasis; D018714:Radiotherapy, Adjuvant; D011994:Recombinant Proteins; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D014604:Uveal Neoplasms / Q000188:drug therapy* / Q000401:mortality
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins